The myositis-specific antibody panel identified the presence of two distinct antibodies: anti-CN1A, which is a biomarker for inclusion body myositis, and anti-NXP2, which is specific to dermatomyositis. The gene discussed is MORC3; the disease is inclusion body myositis.